FDA panel to consider OTC status for GSK's anti-obesity drug

12/14/2005 | USA Today

An FDA advisory committee has scheduled a meeting for late January to consider whether to recommend over-the-counter status for GlaxoSmithKline's obesity drug Xenical. If the panel makes a positive recommendation, the drug -- which works by blocking some fat from being absorbed -- would be the first prescription anti-obesity drug to be made available OTC.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC